Greg Kennelty

Shreyaskumar R. Patel, MD and Jonathan C. Trent, MD discussed the use of trabectedin and the future of the treatment paradigms in soft tissue sarcoma.

Arie Perry, MD, chief of neuropathology at UCSF in San Francisco, California, discusses what oncologists should be aware of when diagnosing patients after these reclassifications, how it could change pathology, as well as a discussion on hereditary tumors.

Maria Ignez Braghiroli, MD, discusses a study that parsed out patients with solely NRAS-mutated colorectal cancer, what the current treatment paradigm is for these patients, and how the mutation status of a patient with colorectal cancer may affect their treatment.

Sibylle Loibl, MD, PhD, discusses the most recent subanalysis of the GeparSepto trial, how the drugs match up in terms of toxicities, and a separate set of data looking at patients with breast cancer who are also pregnant.

Julia White, MD, discusses the upcoming phase II trial, the toxicities associated with the treatment, and the potential for control of these metastases. According to White, the trial is still accruing its 143 patients.

In an interview with <em>Targeted Oncology</em>, Frankie Holmes, MD, discusses HER2-directed therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta).

The antibody drug conjugate XMT-1536 could change the treatment paradigm for both non-small cell lung cancer (NSCLC) and ovarian cancer, according to Donald Bergstrom, MD, PhD.

Michael Choti, MD, discusses the importance of biomarkers when it comes to choosing treatments, which treatments to choose for certain patients with GI cancer, and the improvement of systemic therapy.

Immuno-oncology and the classification of subtypes of gastric cancer could greatly advance treatment efficacy and variation, according to Manish A. Shah, MD.

In an interview with <em>Targeted Oncology</em>, Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses recent developments in polycythemia vera.

Despite some surgical advancements in recurrent glioblastoma, significant progress and a move toward a more personalized approach is still needed, said Jennifer Moliterno Gunel, MD.

To more effectively treat patients with triple negative breast cancer (TNBC), a greater understanding of the disease must first be obtained, said Angela DeMichele, MD, professor of medicine and epidemiology, breast cancer oncologist, University of Pennsylvania.

Cell cycle progression (CCP) and homologous recombination deficiency (HRD) may be linked to bladder cancer recurrences and pathologic complete responses, according to Hristos Kaimakliotis, MD.

Undergoing surgery to prevent ovarian cancer should depend on familial history, as well as age, according to Maurie Markman, MD.

The upcoming HALO 3013 is the first-ever biomarker-driven trial in pancreatic adenocarcinoma, and could potentially change the treatment paradigm for the disease.

The differentiation between squamous and adenocarcinomas in GI cancer could revolutionize the disease&#39;s treatment paradigm, according to John Marshall, MD.

A multicenter trial taking place in Germany seeks to quantify the quality of life for patients with metastatic pancreatic cancer undergoing a combination of nab-paclitaxel and gemcitabine.

While the utilization of immunotherapy in gastric cancer may not be as clear cut as it is in melanoma or lung cancer, Zev Wainberg, MD, illustrates some trials where the therapy type is breaking through.

The search for effective biomarkers is still one of the biggest challenges in cancer, said Janice M. Mehnert, MD.

Immunotherapy may not phase out surgery and chemotherapy as standards of care in cancer, but oncolytic viruses may usher in a new age of treatment.

Atezolizumab proves to be non-toxic and shows major survival advantage in patients with metastatic urothelial bladder cancer.

Data from the phase I HD7 through HD11 trials proves promising enough to move on to phase II.

Two-thirds of patients with chronic myeloid leukemia who ceased to receive the TKI treatment imatinib did not relapse after six months, according to Johan Richter, MD, PhD.

Blinatumomab almost doubles the overall survival of patients with relapsed/refractory acute lymphoblastic leukemia, according to Max Topp, MD.

Understanding the roadblocks of immunotherapy in patients with newly diagnosed, metastatic pancreas cancer could provide oncologists with a new therapeutic tool to add to their armamentarium, according to Eileen O&#39;Reilly, MD.

A recent phase II trial examining nivolumab (Opdivo) in patients with anal cancer seeks to explore the biological makeup, and uncover potential biomarkers in anal cancer.

Early tumor shrinkage is linked to overall survival and could be a stronger surrogate marker than progression-free survival in metastatic colorectal cancer.

Pre-operative chemotherapy alone in esophageal cancer may not be the best choice for patients undergoing resection.

The PD-L1 inhibitor durvalumab demonstrated an objective response rate of 46% for patients with high PD-L1-expressing advanced urothelial bladder cancer.

While PD-L1 has been perceived as an important biomarker in the realm of lung cancer, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, says it still has a long way to go.